Stem Cell Therapy Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 – Skyline…

New Jersey, United States:The Stem Cell Therapy Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Stem Cell Therapy market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Stem Cell Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Stem Cell Therapy market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Leading players of the Stem Cell Therapy market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Stem Cell Therapy market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Stem Cell Therapy market. It also provides useful recommendations for new as well as established players of the Stem Cell Therapy market.

Stem Cell Therapy Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Stem Cell Therapy market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Stem Cell Therapy.

Analysts who have authored the report have segmented the market for Stem Cell Therapy by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Stem Cell Therapy market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=SGN&utm_medium=003

Highlights of TOC:

Overview: In addition to an overview of the Stem Cell Therapy market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Stem Cell Therapy.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Stem Cell Therapy.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Stem Cell Therapy market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Stem Cell Therapy market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=SGN&utm_medium=003

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

Our Trending Reports

Laser Pointer Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Stem Cell Therapy Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 - Skyline...

Pros and Cons of Stem Cell Research – ThoughtCo

Debates over the ethics of embryonic stem cell research have divided scientists, politicians, and religious groups for years.

However, promising developments in other areas of stem cell research have led to solutions that help bypass these ethical barriers and win more support from those against embryonic stem cell research; the newer methods don't require the destruction of blastocysts.

Many parties continue to have strong opinions that trigger ongoing debates about stem cell research, and the following pros and cons provide a snapshot of some the points on each side of the issue.

The excitement about stem cell research is primarily due to the medical benefits in areas ofregenerative medicineand therapeutic cloning. Stem cells provide huge potential for finding treatments and cures to a vast array of medical issues:

Different diseasesincluding cancers, Alzheimer's, Parkinson's, and morecan be treated with stem cells by replacing damaged or diseased tissue. This can include neurons that might affect neurological diseases and even entire organs that need to be replaced.

There is endless potential for scientists to learn about human growth and cell development from studying stem cells. For example, by studying how stem cells develop into specific types of cells, scientists potentially could learn how to treat or prevent relevant ailments.

One of the areas of potential is embryonic treatment. This stage of pregnancy is when many birth defects or other potential issues begin. Studying embryonic stem cells possibly could lead to a better understanding of how embryos develop and maybe even lead to treatments that can identify and address potential problems.

Because the cells can replicate at a high rate, a limited number of initial cells eventually can grow into a much greater number to be studied or used in treatment.

Medical benefits such as regenerating organ tissue and therapeutic cell cloning

May hold the answer to curing various diseases, including Alzheimer's, certain cancers and Parkinson's

Research potential for human cell growth and development to treat a variety of ailments

Possibility of use for embryonic treatment

Requires only a small number of cells because of the fast replication rate

The difficulty of obtaining stem cells and the long period of growth required before use

Unproven treatments often come with high rejection rates

Cost can be prohibitive for many patients

Ethical controversy over use of stem cells from lab-fertilized human eggs

Additional ethical issues regarding the creation of human tissues in a lab, such as cloning

Stem cell research presents problems like any form of research, but most opposition to stem cell research is philosophical and theological, focusing on questions of whether we should be taking science this far:

It's not easy to obtain stem cells. Once harvested from an embryo, stem cells require several months of growth before they can be used. Obtaining adult stem cells, such as from bone marrow, can be painful.

As promising as the field is, stem cell treatments still are unproven, and they often have high rejection rates.

The cost also can be prohibitive for many patients, with a single treatment costing well into the thousands of dollars, as of 2018.

The use of embryonic stem cellsforresearchinvolves the destruction of blastocysts formed from laboratory-fertilized human eggs. For those who believe that life begins at conception, the blastocyst is a human life, and to destroy it is unacceptable and immoral.

A similar theological problem is an idea of creating living tissue in a laboratory and whether that represents humans taking on the role of God. This argument also applies to the potential for human cloning. For those who believe God created people, the prospect of people creating people is troublesome.

In 1998, the first published research paper on the topic reported that stem cells could be taken from human embryos. Subsequent research led to the ability to maintain undifferentiated stem cell lines (pluripotent cells) and techniques for differentiating them into cells specific to various tissues and organs.

The debates over the ethics of stem cell research began almost immediately in 1999, despite reports that stem cells cannot grow into complete organisms.

In 20002001, governments worldwide were beginning to draft proposals and guidelines to control stem cell research and the handling of embryonic tissues and reach universal policies. In 2001, the Canadian Institutes of Health Research (CIHR) drafted a list of recommendations for stem cell research. In the U.S., the Clinton administration drafted guidelines for stem cell research in 2000. Australia, Germany, the United Kingdom, and other countries followed suit and formulated their own policies.

Debates over the ethics of studying embryonic stem cells continued for nearly a decade until the use of adult-derived stem cellsknown as induced pluripotent stem cells (IPSCs)became more prevalent and alleviated those concerns.

In the U.S. since 2011, federal funds can be used to study embryonic stem cells, but such funding cannot be used to destroy an embryo.

Use of adult-derived stem cellsknown as induced pluripotent stem cells (IPSCs)from blood, cord blood, skin, and other tissues have been demonstrated as effective in treating different diseases in animal models. Umbilical cord-derived stem cells obtained from the cord blood also have been isolated and used for various experimental treatments. Another option is uniparental stem cells. Although these cell lines are shorter-lived than embryonic cell lines, uniparental stem cells hold vast potential if enough research money can be directed that way: pro-life advocates do not technically consider them individual living beings.

Two recent developments from stem cell research involve the heart and the blood it pumps. In 2016, researchers in Scotland began working on the possibility of generating red blood cells from stem cells in order to create a large supply of blood for transfusions. A few years earlier, researchers in England began working on polymers derived from bacteria that can be used to repair damaged heart tissue.

The rest is here:
Pros and Cons of Stem Cell Research - ThoughtCo

Stem cells: Therapy, controversy, and research

The idea of a miracle cure and bodies healing themselves holds a particular fascination. Stem cell research brings regenerative medicine a step closer, but many of the ideas and concepts remain controversial. So what are stem cells, and why are they so important?

Stem cells are a type of cell that can develop into many other types of cell. Stem cells can also renew themselves by dividing, even after they have been inactive for a long time.

The human body requires many different types of cell to function, but it does not produce each cell type fully formed and ready to use. Instead, it produces stem cells that have a wide range of possible functions. However, stem cells need to become a specific cell type to be useful.

When a stem cell divides, the new cells may either become another stem cell or a specific cell, such as a blood cell, a brain cell, or a muscle cell.

Scientists call a stem cell an undifferentiated cell because it can become any cell. In contrast, a blood cell, for example, is a differentiated cell, because it is already a specific kind of cell.

In some tissues, stem cells play an essential role in regeneration, as they can divide easily to replace dead cells.

Scientists believe that knowing how stem cells work may lead to possible treatments for conditions, such as diabetes and heart disease.

For instance, if someones heart contains damaged tissue, doctors might be able to stimulate healthy tissue to grow by transplanting laboratory-grown stem cells into the persons heart. This could cause the heart tissue to renew itself.

Researchers on a small-scale study published in the Journal of Cardiovascular Translational Research tested this method.

The results showed a 40 percent reduction of the size of scarred heart tissue caused by heart attacks when doctors transplanted stem cells to the damaged area.

Doctors have always considered this kind of scarring permanent and untreatable.

However, this small study involved only 11 participants. This makes it difficult to tell whether the improvement in heart function resulted from the transplantation of stem cells or whether it was due to something else.

For example, all of the transplants took place while the individuals were undergoing heart bypass surgery, so it is possible that the improvement in heart function was due to the bypass rather than the stem cell treatment.

To investigate further, the researchers plan to do another study. This study will include a control group of people with heart failure who undergo bypass surgery but who do not receive the stem cell treatment.

Another investigation, published in Nature Communications in 2016, has suggested that stem cell therapies could be the basis of personalized diabetes treatment.

In mice and laboratory-grown cultures, researchers successfully produced insulin-secreting cells from stem cells derived from the skin of people with type 1 diabetes.

Jeffrey R. Millman, assistant professor of medicine and biomedical engineering at Washington University School of Medicine and first author, says:

In theory, if we could replace the damaged cells in these individuals with new pancreatic beta cells whose primary function is to store and release insulin to control blood glucose patients with type 1 diabetes wouldnt need insulin shots anymore.

Jeffrey R. Millman

Millman hopes that these stem cell-derived beta cells could be ready for research in humans within 3 to 5 years.

What were envisioning is an outpatient procedure in which some sort of device filled with the cells would be placed just beneath the skin, he said.

Stem cells could have vast potential in developing new therapies.

One way that scientists use stem cells at the moment is in developing and testing new drugs.

The type of stem cells that scientists commonly use for this purpose are called induced pluripotent stem cells.

These are cells that have already undergone differentiation, but which scientists have genetically reprogrammed using viruses, so they can divide and become any cell. In this way, they act like undifferentiated stem cells.

Scientists can grow differentiated cells from these pluripotent stem cells to resemble, for instance, cancer cells. Creating these cells means that scientists can use them to test anti-cancer drugs.

Researchers are already making a wide variety of cancer cells using this method. However, because they cannot yet create cells that mimic cancer cells in a controlled way, it is not always possible to replicate the results precisely.

In recent years, clinics have opened that provide stem cell treatments.

A 2016 study published in Cell Stem Cell counted 570 of these clinics in the United States alone. They offer stem cell-based therapies for disorders ranging from sports injuries to cancer.

However, stem cell therapies are still mostly theoretical rather than evidence-based.

Very few stem cell treatments have even reached the earliest phase of a clinical trial. Scientists are carrying out most of the current research in mice or a petri dish.

Despite this, the U.S. Food and Drug Administration (FDA) allow clinics to inject people with their own stem cells, as long as the cells are intended to perform only their normal function, according to Cell Stem Cell.

Scientists can harvest stem cells in different ways.

Embryonic stem cells come from an embryo that is just a few days old.

Scientists can extract adult stem cells from different types of tissue, including the brain, bone marrow, blood vessels, skeletal muscle, skin, teeth, the gut, the liver, among others.

Amniotic fluid contains stem cells. Many women opt for an amniocentesis test that checks for congenital disabilities before the child is born. If the doctor keeps the fluid, they could use it in the future to treat other conditions either during gestation or after birth.

Induced pluripotent stem cells (iPS cells) are cells that scientists can reprogram to act as stem cells, for use in regenerative medicine.

After collecting the stem cells, scientists usually store them in liquid nitrogen for future use.

Historically, the use of stem cells in medical research has been controversial.

This is because when the therapeutic use of stem cells first came to the publics attention in the late 1990s, scientists were deriving human stem cells from embryos.

Many people disagree with using human embryonic cells for medical research because extracting the stem means destroying the embryo.

This creates complex issues, as people have different beliefs about what constitutes the start of human life.

For some people, life starts when a baby is born, or when an embryo develops into a fetus. Others believe that human life begins at conception, so an embryo has the same moral status and rights as a human adult or child.

President George W. Bush had strong, pro-life religious views, and he banned funding for human stem cell research in 2001.

However, President Obamas administration allowed for a partial rolling back of these research restrictions.

However, by 2006, scientists had already started using pluripotent stem cells. Scientists do not derive these stem cells from embryonic stem cells. As a result, this technique does not have the same ethical concerns.

With this and other recent advances in stem cell technology, attitudes toward stem cell research are slowly beginning to change.

Stem cell research is helping scientists to understand how an organism develops from a single cell, and how healthy cells come to replace defective cells in people and animals.

Many severe medical conditions that occur in humans, such as cancer and congenital disabilities, happen because cells divide abnormally.

A better understanding of stem cells can provide insight into how these diseases arise and possible treatment options.

In June 2016, two researchers took second prize in the materials category of the United Kingdoms Royal Society of Chemistrys emerging technology competition for creating a synthetic biomaterial that stimulates stem cells native to a persons own teeth.

The researchers believe that this material will replace fillings, as the stem cells would prompt the damaged teeth to heal themselves.

Although much more research is necessary before stem cell therapies can become part of regular medical practice, the science around stem cells is developing all the time.

In almost every therapy area, doctors hope that stem cell technology will revolutionize therapeutic norms and introduce at least a new standard of personalized treatment, and maybe even self-healing bodies.

When that might happen, no one is quite ready to say.

Find out more here about stem cells, where they come from, and their possible uses.

See the original post here:
Stem cells: Therapy, controversy, and research

One upside of the coronavirus shutdown, maybe? Fewer voter initiatives – CALmatters

In SummaryInitiative proponents have until the end of April to collect the signatures they need to put their ideas on the ballot and with millions of Californians staying home, some campaigns won't have time to collect enough signatures.

California voters may experience a small silver lining amid the coronavirus pandemic: a shorter November ballot, featuring fewer of the statewide propositions that often put voters in the middle of confusing industry fights.

Initiative proponents have until the end of April to collect the signatures they need to put their ideas on the ballot and with millions of Californians staying home, and practicing social distancing when they go out, it may be impossible for some campaigns to collect enough signatures in time.

People arent out in public, and those who are out in public arent inclined to approach a stranger, take a pen, and stand within 6 feet to put something on the ballot, said Brian Brokaw, a Democratic political consultant who has been involved in several potential ballot measures.

Normally presidential election years attract a slew of initiatives, as campaigns particularly those pushing liberal ideas seek approval from a larger and more diverse electorate. Though we wont know until July exactly how many propositions will be on the ballot, it appears likely that it will be a lot less than in 2016, when Californians voted on 17 statewide ballot measures. Political insiders estimate the final number for 2020 will be in the range of six to 10.

Thats good news for election officials, who could face lower costs for printing and mailing shorter ballots, and for voters who may find the decision-making easier when faced with fewer proposals, said Kim Alexander, president of the nonprofit California Voter Foundation.

Sometimes voting in California can feel like youre taking a test voters can be intimidated by the length and complexity of the ballot, she said. So it could help encourage voter participation if we have fewer complex initiatives sprouting out of special-interest fighting.

People arent out in public, and those who are out in public arent inclined to approach a stranger, take a pen, and stand within 6 feet to put something on the ballot.

So far four measures have qualified for the November ballot, one measure has submitted signatures that are being verified, and another eight have collected at least 25% of the necessary signatures. (Depending on what type of law an initiative would change, it needs either about 623,000 valid signatures or about 997,000 valid signatures.)

Several campaigns have stopped collecting signatures because of the coronavirus shutdown, including those pushing initiatives to allow sports betting, tax plastic packaging to fund environmental programs, continue funding stem cell research and expand Californias data privacy law.

None of them are officially calling it quits. Some may already have enough signatures to make it on the ballot, while others are hoping they can resume collecting signatures in time to get more.

Because the health and wellbeing of Californians is foremost, we paused paid signature gathering efforts for the time being, said Jacob Mejia, a spokesman for the Pechanga Indian tribe that is backing the measure to permit sports betting. Tribal leadership remains committed to bringing this proposal to voters in November and are monitoring developments closely and assessing all options.

But the odds of getting back on the street with pens and clipboards any time soon seem slim, as Gov. Gavin Newsom has said the order to stay home to curb the spread of coronavirus may last two to three months.

Everything is on hold until its safe, said Dan Newman, a spokesman for the plastic recycling measure.

He said the campaign will try to get on the 2022 ballot if it cant resume gathering signatures very soon.

Newsom said this week that companies that are paid to gather signatures for ballot initiatives have asked him to extend the deadlines for submitting signatures so they can have more time to qualify for the November ballot. He was noncommittal, saying only that the question is one of many things hes processing in response to the pandemic.

Continued here:
One upside of the coronavirus shutdown, maybe? Fewer voter initiatives - CALmatters

SENECA BIOPHARMA : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – marketscreener.com

Our Management's Discussion and Analysis of Financial Condition and Results ofOperations or MD&A, is provided in addition to the accompanying financialstatements and notes to assist readers in understanding our results ofoperations, financial condition and cash flows. Our MD&A is organized asfollows:

Trends & Outlook - Discussion of what we view as the overall trends

important to understanding the assumptions and judgments incorporated in

our reported financial results and forecasts.

Results of Operations- Analysis of our financial results comparing the:

(i) year ended December 31, 2019 to the year ended December 31, 2018.

Liquidity and Capital Resources-Analysis of cash flows and discussion of

Our patented technology platform has three core components:

1. Over 300 lines of human, regionally specific neural stem cells, some of

which have the potential to be used to treat serious or life-threatening

diseases through direct transplantation into the central nervous system;

2. Proprietary screening capability - our ability to generate human neural

stem cell lines provides a platform for chemical screening and discovery of

3. Small molecules that resulted from Seneca's neurogenesis screening platform

We generated no revenues from the sale of our proposed therapies for any of theperiods presented.

We have historically generated minimal revenue from the licensing of ourintellectual property to third parties as well as payments under a settlementagreement.

Research and Development Expenses

We have a wholly owned subsidiary in the People's Republic of China thatprimarily oversees our current clinical trial to treat motor deficits due toischemic stroke.

General and Administrative Expenses

Critical Accounting Policies

Comparison of Our Results of Operations for the Years Ended December 31, 2019and 2018

Operating Expenses

Operating expenses for 2019 and 2018 were as follows:

Research and Development Expenses

General and Administrative Expenses

Other income (expense)

Other income, net in 2018 consisted of approximately $3,269,000 of non-cashgains related to the change in the fair value of our liability classified stockpurchase warrants and $79,000 of interest income.

Cash Flows - 2019 compared to 2018

Net Cash Used in Operating Activities

Net Cash Used in Investing Activities

There were no investing activities in the year ended December 31, 2019.

For the year ended December 31, 2018 cash provided by investing activities wascomprised primarily of proceeds from the maturity of our short-term investments.

Net Cash Provided by Financing Activities

For the year ended December 31, 2018, cash provided by financing activitiesconsisted primarily of approximately $1.8 million of net proceeds from ourOctober financing transaction.

Future Liquidity and Needs

Off-balance Sheet Arrangements

None.

Edgar Online, source Glimpses

Continue reading here:
SENECA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - marketscreener.com

Global Animal Stem Cell Therapy Market 2020 Growth Prospects Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA – NJ MMA News

The latest research report entitled Global Animal Stem Cell Therapy Market Growth 2020-2025 released by MRInsights.biz analyzes how the industry has been performing over the last few years and how it will achieve a high growth during the forecast period from 2020 to 2025. The report provides information, statistics, facts and figures, corporate intelligence, economic data, innovation drivers which supports the companies to maximize or minimize the production of goods depending on the states of demand. The report enfolds vital insights into the markets historical and ongoing trends that deliver reliable market estimates to help market players operate their business.

Market Introduction:

The report also highlights market scope, establishment, profitability, maturity, and growth prospects. The report carefully investigates the current scenario of the market and future estimations which spans several market dynamics. The research further explains industry statistics such as global Animal Stem Cell Therapy market size, present valuation, market share, industry trends, and the predicted revenue by the end of the projected period. Our analysts have discovered the business vertical that also explains the desirable growth rate of the market. Factors such as trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, and technological innovations are further discussed.

DOWNLOAD FREE SAMPLE REPORT: https://www.mrinsights.biz/report-detail/232664/request-sample

If you are involved in the global Animal Stem Cell Therapy industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented by Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA, U.S. Stem Cell, Inc, VetCell Therapeutics, J-ARM, Kintaro Cells Power, Celavet Inc., Animal Stem Care, Magellan Stem Cells, Cell Therapy Sciences, Animacel

This report studies the global market status and forecast categorizes the global market size (value & volume) by key players, type, application, and region covering Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Market segment by type covers: Dogs, Horses, Other

Market segment by applications can be divided into: Veterinary Hospitals, Research Organizations

Furthermore, the key entities analyzed and covered within the report includes a large type of applications, industry value and volume, market trends, utility ratio, demand and availability analysis, market growth outlook, manufacturing capacity and price ratio of the global Animal Stem Cell Therapy market during the estimated period from 2020 to 2025. Many inventive sales strategies are listed in the report. This may assistance is capturing numbers and enhancing business perception for the consumers. Segmentation studies include segment attractiveness and profitability. The latest market trends, dynamics, risks, and other influential factors are additionally discovered in the report.

ACCESS FULL REPORT: https://www.mrinsights.biz/report/global-animal-stem-cell-therapy-market-growth-2020-2025-232664.html

Key Target Audience:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Follow this link:
Global Animal Stem Cell Therapy Market 2020 Growth Prospects Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA - NJ MMA News

Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market – Premium Insight, Competitive News Feed Analysis, Company Usability Profiles,…

NEW YORK, March 25, 2020 /PRNewswire/ -- The Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market is expected to grow from USD 3,812.15 Million in 2018 to USD 9,489.21 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 13.91%.

Read the full report: https://www.reportlinker.com/p05872083/?utm_source=PRN

The positioning of the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market including are Antria, Bioheart, Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Neostem, Opexa Therapeutics, Orgenesis, Regeneus, Regenexx, and Tengion.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market

The report answers questions such as:1. What is the market size of Autologous Stem Cell & Non-Stem Cell Based Therapies market in the Global?2. What are the factors that affect the growth in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market over the forecast period?3. What is the competitive position in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?4. Which are the best product areas to be invested in over the forecast period in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?5. What are the opportunities in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?6. What are the modes of entering the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?

Read the full report: https://www.reportlinker.com/p05872083/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-autologous-stem-cell--non-stem-cell-based-therapies-market---premium-insight-competitive-news-feed-analysis-company-usability-profiles-market-sizing--forecasts-to-2025-301029578.html

SOURCE Reportlinker

Here is the original post:
Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles,...

Rewind the clock: Researchers reprogram old cells to youthful state – Daily Sabah

Researchers at Stanford University found that they could reprogram old human cells to a more youthful state with the help of stem cell technology.

According to the study by the universitys School of Medicine, the elderly mice that were experimented on were rejuvenated after the treatment, showing more strength than beforehand.

The treatment involves proteins that are part of embryonic development, also known as Yamanaka factors. These are cells that are used to transform adult cells into a different kind of cell, called an iPS cell, which can transform into nearly any type of cell in the body. Because of this transformative nature, they are essential in regenerative medicine and the discovery of drugs. The researchers hope to use this technique to help with the treatment of diseases like muscle wasting and osteoarthritis which are caused by the aging of the cells.

Subjecting old human cells to this treatment briefly shows that the proteins rewind many of the molecular hallmarks of aging and make them almost identical to the younger cells.

Vittorio Sebastiano, a senior author of the study, said that theyve wondered if they could just rewind the aging clock and now found that by tightly controlling the duration of the exposure to these protein factors, we can promote rejuvenation in multiple human cell types.

Dr. Izpisua Belmonte, who researched Yamanaka factors as well, said that this study is definitively a step forward in the goal of reversing cellular aging.

The research was published online on March 24 in the Nature Communications journal.

See the rest here:
Rewind the clock: Researchers reprogram old cells to youthful state - Daily Sabah

Dad told he has months left to live after stem cell transplant fails – Wales Online

When Phil Huntley started experiencing cold and flu-like symptoms just weeks after his wedding, he initially thought very little of it.

But after visiting his GP and seeing an out-of-hours doctor, his condition deteriorated to such an extent that he collapsed at home.

Tests in hospital confirmed that not only did the 38-year-old have pneumonia and sepsis, but also a rare form of leukaemia which has now spread to his skin and central nervous system.

He has now been told he may have just months left to live after a stem cell transplant failed.

The most recent news has devastated us, but we remain hopeful that against all odds all will be well, said his wife Sian Huntley, 50.

We are determined to live our best lives, make every day count and be grateful for everything.

We are doing our best to make sure the absolute fear that we feel doesn't take over, and instead we breathe and live each moment with joy and gratitude.

Phil, who married Sian in December 2018, said he started suffering with severe night sweats in January 2019 before he became increasingly unwell.

I was dosing myself up on flu relief and still going to work every day. I carried on like that for a few weeks, recalled Phil, a former employee with the National Trust.

Eventually I went to my GP as I knew something wasn't right, but they just said 'something was going around' at the moment and told me to come back in a few days for a blood test if things didn't improve.

After seeing an out-of-hours GP who gave him antibiotics for a suspected chest infection, his condition deteriorated further.

One day it took until 2pm to get out of bed. I managed to find the strength to have a shower. At one point I lost my footing, but moments later everything just went black.

I woke up in Sian's arms who was on the phone to the ambulance.

In A&E at Withybush Hospital in Haverfordwest, blood tests revealed that Phil had pneumonia and sepsis, a condition which causes the body's immune to go into overdrive and start attacking healthy tissue and organs.

It was also discovered that the Solva resident had leukaemia and would need to be transferred to the University Hospital of Wales (UHW) in Cardiff.

Leukaemia was the last thing that crossed my mind, said Phil.

I think the gravity of the whole situation only hit me towards the end of my ambulance ride between Withybush and UHW.

I just felt shock - and such disbelief that I could have laughed. Between myself and Sian we have four children and all I could do is think of them.

While Phil recovered quickly from sepsis, he would need many gruelling rounds of chemotherapy to treat the leukaemia.

I was in UHW for two months to begin with, a week of which was in intensive care, Phil added.

That's all pretty much a blur, and for the first month I didn't leave my bed.

In the second month I had to learn to walk again. When I managed to get myself to the toilet for the first time on my own it was a little personal victory.

Sian added that their four children Dylan, nine; Ben, 10; Katie, 14; and Amy, 16, have all been brilliant while Phil has been unwell.

She said: They all help in any way they can. We know they are struggling and worrying about things. The two older girls have taken on some additional responsibility such as looking after Ben.

But emotionally it has really taken its toll.

Phil, who was later also found to have aspergillosis, a condition which causes major breathing problems, ended up contracting sepsis four times in total following every round of chemotherapy.

Every time he had chemotherapy we were on red alert and would need to take him to hospital, said Sian.

But the staff at Withybush Hospital were amazing and acted straight away to prevent Phil from going into septic shock.

Video Unavailable

Click to playTap to play

Play now

In November 2019, nurses informed Phil that a positive stem cell match had been found for him, giving him hope that he may be cured.

It was a 27-year-old guy from somewhere in Wales and the match was 100%, he said.

But by this point I'd developed leukaemia of the skin, which is only found in around 2% of leukaemia patients. The Cardiff team hadn't really dealt with it previously.

I was in isolation for four to six weeks in UHW for chemotherapy, then I went to Velindre for radiotherapy on my skin, and then I went back to UHW for the transplant to be carried out which was done through an IV drip into my arm.

While Phil started to see signs of improvement early on after the transplant, by mid February 2020 the legions that had vanished from his skin began to reappear.

It's been horrendous, said Sian. At times none of this has seemed real.

His condition is so rare that there is currently no research or medical trials taking place.

A GoFundMe page was set up for the family by close friend Jacqueline Roberts so they can enjoy the time they have left together by going on regular trips around Wales and the UK.

To donate, go to https://www.gofundme.com/f/phil-the-super-hero

But sadly, due to the outbreak of coronavirus and Phil being classified as an extremely at risk patient, he is unable to leave his Pembrokeshire home for at least the next three months.

Sian admitted that she was terrified of picking up the virus and passing it onto her severely unwell husband.

Sian said: We wanted to make some memories as a family, but we are obviously very mindful of the current situation.

We wanted to go to Cornwall as a family but that's obviously not happening now. We are very fortunate to live in a very beautiful part of Wales anyway.

Phil, who is now having monthly injections to slow down the progress of the leukaemia, said he is looking forward to spending some time at home with his family.

I've been either in the hospital or stuck in the house for quite some time now. I just feel sorry for the children as they cannot go anywhere, he said.

Link:
Dad told he has months left to live after stem cell transplant fails - Wales Online

California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus – The Center Square

(The Center Square) California is under a shelter-in-place order due to the coronavirus pandemic, but several ballot initiative campaigns are in the final days or weeks of their signature drives. As of March 23, four citizen-initiated measures have qualified to appear on the ballot in November. An additional nine ballot initiatives could receive enough signatures to appear on the ballot.

The deadline for signature verification is June 25, 2020. However, the process of verifying signatures can take multiple months. Secretary of State Alex Padilla (D) recommends that campaigns file signatures no later than April 21. Campaigns that file signatures after the deadline can still have their proposals appear on the ballot for November 8, 2022.

Gov. Gavin Newsom (D) has directed residents to remain at home, except as needed for food, medicine, and other services deemed essential, due to the pandemic. The California Department of Health has advised that non-essential gatherings be postponed or canceled, and the CDC is recommending that people maintain distance between each other.

Jamie Court, president of Consumer Watchdog, stated, We were getting 70,000 signatures a week until a couple of weeks ago, when it almost stopped. According to Fred Kimball, owner of the signature-gathering firm Kimball Petition Management, Were all flying by the seat of our pants. No one has ever seen this.

Campaigns behind the following nine citizen-initiated measures are seeking a place for their proposals on the general election ballot. Coronavirus, however, could have the effect of limiting the number of signatures that an individual petitioner can collect, especially for campaigns that didnt launch until January 2020.

Property Tax Transfers and Exemptions Initiative (#19-0003): The campaign Homeownership for Families and Tax Savings for Seniors filed 1.43 million signatures on March 4. At least 997,139 signatures need to be valid. The ballot measure would change how tax assessments are transferred between properties for eligible homebuyers and address resetting tax assessments to fair market value on inherited properties and when corporations and other entities acquire control of properties. Homeownership for Families and Tax Savings for Seniors, which is associated with the California Association of Realtors, has raised $12.08 million.

Tax on Commercial and Industrial Properties for Education and Local Government Funding Initiative (#19-0008): An earlier version of the citizen-initiated measure has qualified for the ballot, but the campaign Schools and Communities First is seeking to replace the initiative with an amended version. The campaign needs to file at least 997,139 valid signatures. Schools and Communities First has raised $17.13 million. Both versions of the ballot initiative would amend the state constitution to require commercial and industrial properties, except those zoned as commercial agriculture, to be taxed based on their market value.

Consumer Personal Information Law and Agency Initiative (#19-0021): The ballot initiative seeks to expand the provisions of the California Consumer Privacy Act (CCPA), which was passed in 2018. The campaign Californians for Consumer Privacy raised $3.42 million for this years effort. Robin Swanson, a consultant for the campaign, said, Were in pretty good shape with the numbers that we have, but are adhering to public health requirements and putting public safety first. Like most ballot measure campaigns out there, wed always love more signatures, but were dealing with a stark new reality while the state is on lockdown. At least 623,212 valid signatures need to be filed for the ballot measure.

Stem Cell Research Institute Bond Initiative (#19-0022): Californians for Stem Cell Research, Treatments, and Cures is backing a ballot initiative to issue $5.5 billion in general obligation bonds for the state's stem cell research institute. Spokesperson Sarah Melbostad said the campaigns signature drive has been suspended due to the coronavirus pandemic. "In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being. ... Were confident that we still have time to qualify and plan to proceed accordingly, said Melbostad. Proponents have raised $5.28 million. The campaign needs to collect at least 623,212 valid signatures.

Dialysis Clinic Requirements and Consent to Close Initiative (#19-0025): Californians for Kidney Dialysis Patient Protection, which backed a defeated dialysis-related initiative in 2018, has raised $5.38 million for the new effort. The campaign needs at least 623,212 valid signatures.

App-Based Drivers Regulations Initiative (#19-0026): With $110.58 million, Protect App-Based Drivers and Services has collected over 1 million signatures, of which 623,212 need to be valid. The campaign has the support of Uber, Lyft, Doordash, Instacart, and Postmates. The ballot measure would consider app-based drivers to be independent contractors and enact several wage and labor policies that would affect app-based drivers and companies. Spokesperson Stacy Wells said, We were really lucky. We got our signatures in fast and were able to get off the streets in seven weeks.

Packaging Waste Reduction Regulations Initiative (#19-0028): The ballot measure would require CalRecycle, in consultation with other agencies, to adopt regulations that reduce the use of product packaging, single-use packaging, and single-use dishes and utensils. The campaign Clean Coasts, Clean Water, Clean Streets has raised $3.26 million. At least 623,212 valid signatures need to be collected.

Legalize Sports Betting on American Indian Lands Initiative (#19-0029): The Coalition to Authorize Regulated Sports Wagering, with the support of several tribal governments, has raised $7.5 million for a ballot measure to legalize sports betting at American Indian gaming casinos and licensed racetracks. The effort to collect 997,139 valid signatures began on January 21, 2020. We are at nearly 1 million signatures and were on a trajectory to reach our goal well ahead of the deadline before the unprecedented orders around COVID-19, said Jacob Mejia, a spokesperson for the campaign. He added, The health and well-being of Californians is foremost. Thus, paid signature-gathering efforts have paused for the time being.

Read the original:
California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus - The Center Square